Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

NCT02767804 is registered in ClinicalTrials.gov with Xcovery Holdings, Inc. as lead sponsor.

NCT NCT02767804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02767804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Lead sponsor
Xcovery Holdings, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 30, 2016
Completion date
December 31, 2025
Enrollment
290 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer